We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02781584
Recruitment Status : Completed
First Posted : May 24, 2016
Results First Posted : February 2, 2022
Last Update Posted : March 16, 2022
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences

Brief Summary:
The primary objective of this study is to evaluate the safety and tolerability of selonsertib, firsocostat, cilofexor, fenofibrate and/or Vascepa® in adults with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).

Condition or disease Intervention/treatment Phase
Nonalcoholic Steatohepatitis (NASH) Nonalcoholic Fatty Liver Disease (NAFLD) Drug: SEL Drug: FIR Drug: CILO Drug: FENO Drug: VAS Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 220 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Cohorts 1-6 and 9 will be enrolled sequentially while Cohorts 7 and 8 will be randomized in parallel. Cohorts 10 and 11 will be randomized in parallel. Cohorts 12 and 13 will be randomized in parallel.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Actual Study Start Date : June 13, 2016
Actual Primary Completion Date : December 17, 2020
Actual Study Completion Date : December 17, 2020


Arm Intervention/treatment
Experimental: Cohort 1: SEL 18 mg (Non-cirrhotic)
Non-cirrhotic participants will receive selonsertib (SEL) 18 mg tablet orally once daily for 12 weeks.
Drug: SEL
Administered orally once daily
Other Name: GS-4997

Experimental: Cohort 2: FIR 20 mg (Non-cirrhotic)
Non-cirrhotic participants will receive firsocostat (FIR) 20 mg tablet orally once daily for 12 weeks.
Drug: FIR
Administered orally once daily
Other Name: GS-0976

Experimental: Cohort 3: CILO 30 mg (Non-cirrhotic)
Non-cirrhotic participants will receive cilofexor (CILO) 30 mg tablet once daily for 12 weeks.
Drug: CILO
Administered orally once daily
Other Name: GS-9674

Experimental: Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic)
Non-cirrhotic participants will receive SEL 18 mg tablet + CILO 30 mg tablet once daily for 12 weeks.
Drug: SEL
Administered orally once daily
Other Name: GS-4997

Drug: CILO
Administered orally once daily
Other Name: GS-9674

Experimental: Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic)
Non-cirrhotic participants will receive SEL 18 mg tablet + FIR 20 mg tablet once daily for 12 weeks.
Drug: SEL
Administered orally once daily
Other Name: GS-4997

Drug: FIR
Administered orally once daily
Other Name: GS-0976

Experimental: Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic)
Non-cirrhotic participants will receive CILO 30 mg tablet + FIR 20 mg tablet once daily for 12 weeks.
Drug: FIR
Administered orally once daily
Other Name: GS-0976

Drug: CILO
Administered orally once daily
Other Name: GS-9674

Experimental: Cohort 7: CILO 20 mg (Cirrhotic)
Participants with Child-Pugh-Turcotte Class A cirrhosis will receive FIR 20 mg tablet once daily for 12 weeks.
Drug: FIR
Administered orally once daily
Other Name: GS-0976

Experimental: Cohort 8: CILO 30 mg (Cirrhotic)
Participants with Child-Pugh-Turcotte Class A cirrhosis will receive CILO 30 mg tablet once daily for 12 weeks.
Drug: CILO
Administered orally once daily
Other Name: GS-9674

Experimental: Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic)
Non-cirrhotic participants will receive SEL 18 mg tablet + FIR 20 mg tablet + CILO 30 mg tablet once daily for 12 weeks.
Drug: SEL
Administered orally once daily
Other Name: GS-4997

Drug: FIR
Administered orally once daily
Other Name: GS-0976

Drug: CILO
Administered orally once daily
Other Name: GS-9674

Experimental: Cohort 10: FIR 20 mg + FENO 48 mg
Participants will receive fenofibrate (FENO) 48 mg tablet orally once daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet + FENO 48 mg tablet orally once daily for 24 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.
Drug: FIR
Administered orally once daily
Other Name: GS-0976

Drug: FENO
Administered orally once daily

Experimental: Cohort 11: FIR 20 mg + FENO 145 mg
Participants will receive FENO 145 mg tablet orally once daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet + FENO 145 mg tablet orally once daily for 24 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.
Drug: FIR
Administered orally once daily
Other Name: GS-0976

Drug: FENO
Administered orally once daily

Experimental: Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g
Participants will receive Vascepa® (VAS) 2 g capsule orally twice daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet once daily + CILO 30 mg tablet once daily + VAS 2 g capsule twice daily for 6 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.
Drug: FIR
Administered orally once daily
Other Name: GS-0976

Drug: CILO
Administered orally once daily
Other Name: GS-9674

Drug: VAS
Administered orally two times daily

Experimental: Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg
Participants will receive FENO 145 mg tablet orally once daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet once daily + CILO 30 mg tablet once daily + FENO 145 mg tablet orally once daily for 6 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.
Drug: FIR
Administered orally once daily
Other Name: GS-0976

Drug: CILO
Administered orally once daily
Other Name: GS-9674

Drug: FENO
Administered orally once daily




Primary Outcome Measures :
  1. Percentage of Participants Who Experienced Treatment-Emergent Adverse Events [ Time Frame: Cohorts 1-9: First dose date up to 12 weeks plus 30 days; Cohorts 10-11: First dose date up to 26 weeks plus 30 days; Cohorts 12-13: First dose date up to 8 weeks plus 30 days. For Cohorts 10-13, the first dose date included the Pre-treatment Phase. ]

    Treatment-emergent AEs were defined as events that met 1 or both of the following criteria:

    • Any AEs with onset dates on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug
    • Any AEs leading to premature discontinuation of study drug

  2. Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events [ Time Frame: Cohorts 1-9: First dose date up to 12 weeks plus 30 days; Cohorts 10-11: First dose date up to 26 weeks plus 30 days; Cohorts 12-13: First dose date up to 8 weeks plus 30 days. For Cohorts 10-13, the first dose date included the Pre-treatment Phase. ]

    A treatment emergent serious adverse event (SAE) was defined as an event that, at any dose, results in the following:

    • Death
    • Life-threatening
    • In-patient hospitalization or prolongation of existing hospitalization
    • Persistent or significant disability/incapacity
    • A congenital anomaly/birth defect
    • A medically important event or reaction

  3. Percentage of Participants Who Experienced Grade 3 or Higher Laboratory Abnormalities [ Time Frame: Cohorts 1-9: First dose date up to 12 weeks plus 30 days; Cohorts 10-11: First dose date up to 26 weeks plus 30 days; Cohorts 12-13: First dose date up to 8 weeks plus 30 days. For Cohorts 10-13, the first dose date included the Pre-treatment Phase. ]
    Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days for subjects who permanently discontinued study drug. If baseline laboratory data were missing, then any abnormality of at least Grade 1 was considered treatment emergent. Graded laboratory abnormalities were defined using the grading scheme in the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 for Cohorts 1-9 and CTCAE Version 5.0 for Cohorts 10-13.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Males and females between 18-75 years of age (Cohorts 1-9: 18-75 years and Cohorts 10-13: ≥ 18 years); inclusive based on the date of the screening visit
  • Willing and able to provide informed consent prior to any study specific procedures being performed
  • For Cohorts 1 through 6 and 9, individuals must meet the following conditions:

    • Clinical diagnosis of nonalcoholic fatty liver disease (NAFLD)
    • Screening FibroTest® < 0.75, unless a historical liver biopsy within 12 months of Screening does not reveal cirrhosis. In individuals with Gilbert's syndrome or hemolysis, FibroTest® will be calculated using direct bilirubin instead of total bilirubin,
    • Screening magnetic resonance imaging - proton density fat fraction (MRI-PDFF) with ≥ 10% steatosis,
    • Screening magnetic resonance elastography (MRE) with liver stiffness ≥ 2.88 kPa, OR
    • A historical liver biopsy within 12 months of Screening consistent with NASH (defined as the presence of steatosis, inflammation, and ballooning) with stage 2-3 fibrosis according to the NASH Clinical Research Network (CRN) classification (or equivalent), AND
    • No documented weight loss > 5% between the date of the liver biopsy and Screening;
  • For Cohorts 7 and 8, individuals must have a clinical diagnosis of NAFLD and have at least one of the following criteria:

    • Screening MRE with liver stiffness ≥ 4.67 kPa,
    • A historical FibroScan® ≥ 14 kPa within 6 months of Screening,
    • Screening FibroTest® ≥ 0.75,
    • A historical liver biopsy consistent with stage 4 fibrosis according to the NASH CRN classification (or equivalent);
  • For Cohorts 10 and 11, individuals must have a clinical diagnosis of NAFLD and meet at least two criteria for metabolic syndrome modified from the NCEP ATP III Guidelines and one of the following criteria at Screening:

    • A historical liver biopsy within 6 months of Screening consistent with NASH and bridging fibrosis (F3) or within 12 months of Screening consistent with NASH and compensated cirrhosis (F4) in the opinion of the investigator,
    • Screening liver stiffness by MRE ≥ 3.64 kPa;
    • Screening liver stiffness by FibroScan® ≥ 9.9 kPa;
  • For Cohorts 12 and 13, individuals must have a clinical diagnosis of NAFLD/NASH and at least two criteria for metabolic syndrome as modified from the NCEPT ATP III Guidelines, OR one of the following criteria:

    • A historical liver biopsy within 6 months of Screening consistent with NASH for individuals without compensated cirrhosis (F4); or within 12 months of Screening consistent with NASH for individuals with compensated cirrhosis (F4) in the opinion of the investigator,
    • A historical MRE with liver stiffness ≥ 2.88 kPa within 6 months of Screening,
    • A historical FibroScan® with liver stiffness ≥ 9.9 kPa within 6 months of Screening, AND
    • No documented weight loss > 5% between the date of the historical liver biopsy, historical MRE, or historical FibroScan® and Screening;
  • Platelet count ≥ 100,000/µL;
  • Serum creatinine < 2 mg/dL (Cohorts 1-9) at Screening;
  • Estimated glomerular filtration rate (eGFR) ≥ 80 mL/min (Cohorts 10-11) or ≥ 60 mL/min (Cohorts 12-13), as calculated by the Cockcroft-Gault equation at Screening;
  • For Cohorts 10-13, serum triglyceride level ≥ 150 mg/dL at Screening.

Key Exclusion Criteria:

  • Pregnant or lactating females
  • Other causes of liver disease including autoimmune, viral, and alcoholic liver disease
  • Any history of decompensated liver disease, including ascites, hepatic encephalopathy or variceal bleeding
  • For Cohorts 7-8, 10-13, Child-Pugh-Turcotte (CPT) score > 6
  • History of liver transplantation
  • History of hepatocellular carcinoma;
  • Weight reduction surgery in the past 2 years or planned during the study;
  • Documented weight loss > 5% between the date of the historical liver biopsy and Screening, if applicable;
  • Body Mass Index (BMI) < 18 kg/m2;
  • ALT > 5 x ULN at Screening;
  • For Cohorts 10-13, HbA1c ≥ 9.5% (or serum fructosamine ≥ 381 µmol if HbA1c is unable to be resulted) at Screening;
  • For Cohorts 10-13, hemoglobin ≤ 10.6 g/dL at Screening;
  • INR > 1.2 (Cohorts 1-9) or INR > 1.4 (Cohorts 10-13) at Screening, unless on anticoagulation therapy;
  • Total bilirubin > 1x ULN (Cohorts 1 through 6 and 9), >1.5 x ULN (Cohorts 7 and 8), or >1.3 x ULN (Cohorts 10-13) except in confirmed cases of Gilbert's syndrome;
  • Triglycerides ≥ 500 mg/dL (Cohorts 5-8 and 10-13) or ≥ 250 mg/dL (Cohort 9) at Screening;
  • Model for End-Stage Liver Disease (MELD) score > 12 at Screening (Cohorts 10 -13), unless due to an alternate etiology such as therapeutic anticoagulation;
  • Chronic hepatitis B (HBsAg positive);
  • Chronic hepatitis C (HCV RNA positive). individuals cured of HCV infection less than 2 years prior to the Screening visit are not eligible (Cohorts 10-13);
  • HIV Ab positive;
  • Presence of gallstones within 6 months of Screening (Cohorts 10-13);
  • Alcohol consumption greater than 21 oz/week for males or 14 oz/week for females (1oz/30 mL of alcohol is present in 1 12oz/360 mL beer, 1 4oz/120 mL glass of wine, and a 1 oz/30 mL measure of 40% proof alcohol);
  • Positive urine screen for amphetamines, cocaine or opiates (i.e., heroin, morphine) at Screening. Individuals on stable methadone or buprenorphine maintenance treatment for at least 6 months prior to Screening may be included in the study. Individuals with a positive urine drug screen due to prescription opioid-based medication are eligible if the prescription and diagnosis are reviewed and approved by the investigator;
  • Unstable cardiovascular disease;
  • History of intestinal resection of the extent that would result in malabsorption;
  • Use of any prohibited concomitant medications as described in the protocol;
  • History of a malignancy within 5 years of Screening with the following exceptions:

    • Adequately treated carcinoma in situ of the cervix,
    • Adequately treated basal or squamous cell cancer or other localized non-melanoma skin cancer.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02781584


Locations
Layout table for location information
United States, Arizona
Arizona Liver Health
Chandler, Arizona, United States, 85224
United States, California
Altman Clinical and Translational Research Clinic
La Jolla, California, United States, 92093
Ruane Clinical Research Group Inc.
Los Angeles, California, United States, 90036
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
Stanford Hospital and Clinics (SHC)
Stanford, California, United States, 94305
United States, Florida
Florida Research Institute
Lakewood Ranch, Florida, United States, 34211
United States, Louisiana
Delta Research Partners, LLC
Bastrop, Louisiana, United States, 71220
United States, Tennessee
Gastro One
Germantown, Tennessee, United States, 38138
Quality Medical Research
Nashville, Tennessee, United States, 37211
United States, Texas
Pinnacle Clinical Research, PLLC
Live Oak, Texas, United States, 78233
American Research Corporation at the Texas Liver Institute
San Antonio, Texas, United States, 78215
Pinnacle Clinical Research, PLLC
San Antonio, Texas, United States, 78229
New Zealand
Auckland Clinical Studies Ltd
Auckland, New Zealand, 1010
Sponsors and Collaborators
Gilead Sciences
Investigators
Layout table for investigator information
Study Director: Gilead Study Director Gilead Sciences
  Study Documents (Full-Text)

Documents provided by Gilead Sciences:
Study Protocol  [PDF] September 11, 2019

Publications of Results:
Lawitz E, Bhandari BR, Ruane P, Kohli A, Harting E, Jia C, et al. Fenofibrate is Safe and Mitigates Increases in Serum Triglycerides in NASH Patients Treated with the Combination of the ACC Inhibitor Firsocostat and the FXR Agonist Cilofexor: A Randomized Trial. Poster presented at: The European Association for the Study of the Liver (EASL): International Liver Congress; June 23-26, 2021; Virtual Meeting.

Other Publications:
Lawitz E, Neff G, Ruane P, Ziad Y, Jia C, Chuang J, et al. Fenofibrate Mitigates Increases in Serum Triglycerides Due to the ACC Inhibitor Firsocostat in Patients with Advanced Fibrosis Due to NASH. Poster presented at: The American Association for the Study of Liver Diseases (AASLD): The Liver Meeting; November 8-12, 2019; Boston, MA.
Lawitz E, Herring R, Younes ZH, Gane E, Ruane P, Schall RA, et al. Proof of Concept Study of an Apoptosis-Signal Regulating Kinase (ASK1) Inhibitor (Selonsertib) in Combination With An Acetyl-CoA Carboxylase Inhibitor (GS-0976) or a Farnesoid X Receptor Agonist (GS-9674) in Nash [Abstract PS-105]. European Association for the Study of the Liver (EASL); 2018 11-15 April; Paris, France.
Lawitz E, Li K, Tarrant JM, Vimal M, Xu R, Song Q, et al. Hepatic de Novo Lipogenesis is Elevated in Patients with NASH Independent of Disease Severity [Abstract 2217]. American Association for the Study of Liver Diseases (AASLD); 2017 20-24 October Washington, DC.
Lawitz EJ, Poordad F, Coste A, Loo N, Djedjos CS, McColgan B, et al. Acetyl-CoA carboxylase (ACC) inhibitor GS-0976 leads to suppression of hepatic de novo lipogenesis and significant improvements in MRI-PDFF, MRE, and markers of fibrosis after 12 weeks of therapy in patients with NASH [Abstract GS-009]. The International Liver Congress™ 2017: European Association for the Study of the Liver (EASL); 2017 19-23 April; Amsterdam, the Netherlands.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Gilead Sciences
ClinicalTrials.gov Identifier: NCT02781584    
Other Study ID Numbers: GS-US-384-3914
First Posted: May 24, 2016    Key Record Dates
Results First Posted: February 2, 2022
Last Update Posted: March 16, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Digestive System Diseases
Firsocostat
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action